Literature DB >> 10518592

Mimicry of erythropoietin by a nonpeptide molecule.

S A Qureshi1, R M Kim, Z Konteatis, D E Biazzo, H Motamedi, R Rodrigues, J A Boice, J R Calaycay, M A Bednarek, P Griffin, Y D Gao, K Chapman, D F Mark.   

Abstract

Erythropoietin (EPO) controls the proliferation and differentiation of erythroid progenitor cells into red blood cells. EPO induces these effects by dimerization of the EPO receptors (EPOR) present on these cells. To discover nonpeptide molecules capable of mimicking the effects of EPO, we identified a small molecule capable of binding to one chain of EPOR and used it to synthesize molecules capable of inducing dimerization of the EPOR. We first identified compound 1 (N-3-[2-(4-biphenyl)-6-chloro-5-methyl]indolyl-acetyl-L-lysine methyl ester) by screening the in-house chemical collection for inhibitors of EPO binding to human EPOR and then prepared compound 5, which contains eight copies of compound 1 held together by a central core. Although both compounds inhibited EPO binding of EPOR, only compound 5 induced dimerization of soluble EPOR. Binding of EPO to its receptor in cells results in activation of many intracellular signaling molecules, including transcription factors like signal transducer and activator of transcription (STAT) proteins, leading to growth and differentiation of these cells. Consistent with its ability to induce dimerization of EPOR in solution, compound 5 exhibited much of the same biological activities as EPO, such as (i) the activation of a STAT-dependent luciferase reporter gene in BAF3 cells expressing human EPOR, (ii) supporting the proliferation of several tumor cell lines expressing the human or mouse EPOR, and (iii) the in vitro differentiation of human progenitor cells into colonies of erythrocytic lineage. These data demonstrate that a nonpeptide molecule is capable of inducing EPOR dimerization and mimicking the biological activities of EPO.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10518592      PMCID: PMC18428          DOI: 10.1073/pnas.96.21.12156

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Rational design of potent antagonists to the human growth hormone receptor.

Authors:  G Fuh; B C Cunningham; R Fukunaga; S Nagata; D V Goeddel; J A Wells
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

Review 2.  Erythropoietin in chronic renal failure.

Authors:  F Valderrábano
Journal:  Kidney Int       Date:  1996-10       Impact factor: 10.612

3.  Cytokines and growth factors signal through tyrosine phosphorylation of a family of related transcription factors.

Authors:  P Rothman; B Kreider; M Azam; D Levy; U Wegenka; A Eilers; T Decker; F Horn; H Kashleva; J Ihle
Journal:  Immunity       Date:  1994-09       Impact factor: 31.745

4.  Small peptides as potent mimetics of the protein hormone erythropoietin.

Authors:  N C Wrighton; F X Farrell; R Chang; A K Kashyap; F P Barbone; L S Mulcahy; D L Johnson; R W Barrett; L K Jolliffe; W J Dower
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

5.  Dendrimer-supported combinatorial chemistry.

Authors:  R M Kim; M Manna; S M Hutchins; P R Griffin; N A Yates; A M Bernick; K T Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

6.  STAT protein complexes activated by interferon-gamma and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties.

Authors:  P Lamb; H M Seidel; J Haslam; L Milocco; L V Kessler; R B Stein; J Rosen
Journal:  Nucleic Acids Res       Date:  1995-08-25       Impact factor: 16.971

7.  Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells.

Authors:  M J Koury; M C Bondurant
Journal:  J Cell Physiol       Date:  1988-10       Impact factor: 6.384

8.  Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway.

Authors:  A Yoshimura; M Ichihara; I Kinjyo; M Moriyama; N G Copeland; D J Gilbert; N A Jenkins; T Hara; A Miyajima
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

9.  Establishment and erythroid differentiation of a cytokine-dependent human leukemic cell line F-36: a parental line requiring granulocyte-macrophage colony-stimulating factor or interleukin-3, and a subline requiring erythropoietin.

Authors:  S Chiba; F Takaku; T Tange; K Shibuya; C Misawa; K Sasaki; K Miyagawa; Y Yazaki; H Hirai
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

10.  Interleukin-3 signals through multiple isoforms of Stat5.

Authors:  M Azam; H Erdjument-Bromage; B L Kreider; M Xia; F Quelle; R Basu; C Saris; P Tempst; J N Ihle; C Schindler
Journal:  EMBO J       Date:  1995-04-03       Impact factor: 11.598

View more
  16 in total

Review 1.  Receptor recognition by gp130 cytokines.

Authors:  J Bravo; J K Heath
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

Review 2.  Drugs for increasing oxygen and their potential use in doping: a review.

Authors:  Aurelie Gaudard; Emmanuelle Varlet-Marie; Francoise Bressolle; Michel Audran
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 3.  Ligand discovery and virtual screening using the program LIDAEUS.

Authors:  P Taylor; E Blackburn; Y G Sheng; S Harding; K-Y Hsin; D Kan; S Shave; M D Walkinshaw
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 4.  Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era.

Authors:  Evanthia Diamanti-Kandarakis; Panagiotis A Konstantinopoulos; Joanna Papailiou; Stylianos A Kandarakis; Anastasios Andreopoulos; Gerasimos P Sykiotis
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

5.  Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jerome Rossert; Stefano Luminari; Andrew M Evens; Francesco Locatelli; Steven M Belknap; June M McKoy; E Alison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

6.  Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor.

Authors:  James L Miller; Timothy J Church; Dmitri Leonoudakis; Karen Lariosa-Willingham; Normand L Frigon; Connie S Tettenborn; Jeffrey R Spencer; Juha Punnonen
Journal:  Mol Pharmacol       Date:  2015-05-27       Impact factor: 4.436

7.  NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction.

Authors:  S Donald Emerson; Robert Palermo; Chao-Min Liu; Jefferson W Tilley; Li Chen; Waleed Danho; Vincent S Madison; David N Greeley; Grace Ju; David C Fry
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

Review 8.  Understanding cytokine and growth factor receptor activation mechanisms.

Authors:  Mariya Atanasova; Adrian Whitty
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-10-09       Impact factor: 8.250

Review 9.  Erythropoietin: physiology and molecular mechanisms.

Authors:  Robert N Foley
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

10.  A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses.

Authors:  Tamas Bartfai; M Margarita Behrens; Svetlana Gaidarova; Janell Pemberton; Alexander Shivanyuk; Julius Rebek
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.